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INTRODUCTION 
The branch of science concerned with the substance of which matter is 
composed, the investigation of their properties and reactions, and the use of 
such reactions to form new substances are called as chemistry. Chemistry is 
the central science because it bridges other natural sciences, including 
physics, geology and biology. The atom is the basic unit of chemistry. It 
consists of a dense core called atomic nucleus surrounded by a space called 
the electron cloud. The nucleus is made up of positively charged protons and 
uncharged neutrons, while the electron cloud consists of negatively charged 
electrons which orbit the nucleus. In a neutral atom, the negatively charged 
electrons balance out the positive charge of the protons. A chemical element 
is a pure substance which is composed of a single type of atom, characterized 
by its particular number of protons in the nuclei of its atoms, known as atomic 
number and represented by the symbol Z. The mass number is the sum of the 
number of protons and neutrons in a nucleus. Although all the nuclei of all 
atoms belonging to one element will have the same atomic number, they may 
not necessarily have the same mass number, atoms of an element which 
have different mass number are known as isotops. A pure chemical 
substance composed of more than one element is called as compound. 
Drug design 
             Drug design, often referred to as rational drug design or 
simply rational design, is the inventive process of finding new medications 
based on the knowledge of a biological target.The drug is most commonly 
an organic small molecule that activates or inhibits the function of a bio 
molecule such as a protein, which in turn results in a therapeutic benefit to 
the patient. In the most basic sense, drug design involves the design of 
molecules that are complementary in shape and charge to the bio molecular 
target with which they interact and therefore will bind to it. Drug design 
frequently but not necessarily relies on computer modeling techniques. This 
type of modeling is sometimes referred to as computer-aided drug design. 
Finally, drug design that relies on the knowledge of the three-dimensional 
structure of the bio molecular target is known as structure-based drug 
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design. In addition to small molecules, biopharmaceuticals and especially 
therapeutic antibodies are an increasingly important class of drugs and 
computational methods for improving the affinity, selectivity, and stability of 
this protein-based therapeutics have also been developed.  
 
 
 
FIG.1: FLOWCHART OF A USUAL CLUSTERING ANALYSIS FOR 
STRUCTURE-BASED DRUG DESIGN 
 
MOLECULAR DOCKING 
In the field of molecular modeling, docking is a method which predicts 
the preferred orientation of one molecule to a second when bound to each 
other to form a stable complex. Knowledge of the preferred orientation in turn 
may be used to predict the strength of association or binding affinity between 
two molecules using, for example, scoring functions. 
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FIG.2: SCHEMATIC ILLUSTRATION OF DOCKING A SMALL MOLECULE 
LIGAND (GREEN) TO A PROTEIN TARGET (BLACK) PRODUCING A 
STABLE COMPLEX. 
 
The associations between biologically relevant molecules such 
as proteins, nucleic acids, carbohydrates, and lipids play a central role 
in signal transduction. Furthermore, the relative orientation of the two 
interacting partners may affect the type of signal produced 
(e.g., agonism vs antagonism). Therefore, docking is useful for predicting both 
the strength and type of signal produced. 
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Molecular docking is one of the most frequently used methods 
in structure-based drug design, due to its ability to predict the binding-
conformation of small molecule ligands to the appropriate target binding site. 
Characterization of the binding behavior plays an important role in rational 
design of drugs as well as to elucidate fundamental biochemical processes. 
Docking approaches1 
Two approaches are particularly popular within the molecular docking 
community. One approach uses a matching technique that describes the 
protein and the ligand as complementary surfaces. The second approach 
simulates the actual docking process in which the ligand-protein pair wise 
interaction energies are calculated. Both approaches have significant 
advantages as well as some limitations. 
Mechanics of docking 
To perform a docking screen, the first requirement is a structure of the 
protein of interest. Usually the structure has been determined using a 
biophysical technique such as x-ray crystallography or NMR spectroscopy, 
but can also derive from homology modeling construction. This protein 
structure and a database of potential ligands serve as inputs to a docking 
program. The success of a docking program depends on two components: 
the search algorithm and the scoring function. 
Search algorithm2  
The  search space in theory consists of all possible orientations 
and conformations of the protein paired with the ligand. However, in practice 
with current computational resources, it is impossible to exhaustively explore 
the search space—this would involve enumerating all possible distortions of 
each molecule (molecules are dynamic and exist in an ensemble of 
conformational states) and all possible rotational and translational orientations 
of the ligand relative to the protein at a given level of granularity. Most docking 
programs in use account for the whole conformational space of the ligand 
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(flexible ligand), and several attempt to model a flexible protein receptor. Each 
"snapshot" of the pair is referred to as a pose. 
A variety of conformational search strategies have been applied to the 
ligand and to the receptor. These include: 
• Systematic or stochastic torsional searches about rotatable bonds 
• Molecular dynamics simulations 
• Genetic algorithms to "evolve" new low energy conformations and 
where the score of each pose acts as the fitness function used to 
select individuals for the next iteration. 
Ligand flexibility 
Conformations of the ligand may be generated in the absence of the 
receptor and subsequently docked or conformations may be generated on-
the-fly in the presence of the receptor binding cavity, or with full rotational 
flexibility of every dihedral angle using fragment based docking. Force 
field energy evaluations are most often used to select energetically 
reasonable conformations, but knowledge-based methods have also been 
used. 
Receptor flexibility: 
Computational capacity has increased dramatically over the last 
decade making possible the use of more sophisticated and computationally 
intensive methods in computer-assisted drug design. However, dealing with 
receptor flexibility in docking methodologies is still a thorny issue. The main 
reason behind this difficulty is the large number of degrees of freedom that 
have to be considered in this kind of calculations. Neglecting it, however, 
leads to poor docking results in terms of binding pose prediction. Multiple 
static structures experimentally determined for the same protein in different 
conformations are often used to emulate receptor flexibility.  
Alternatively rotamer libraries of amino acid side chains that surround 
the binding cavity may be searched to generate alternate but energetically 
reasonable protein conformations.  
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Application3 
A binding interaction between a small molecule ligand and an enzyme 
protein may result in activation or inhibition of the enzyme. If the protein is a 
receptor, ligand binding may result in agonism or antagonism. Docking is 
most commonly used in the field of drug design — most drugs are 
small organic molecules, and docking may be applied to: 
• Hit identification – docking combined with a scoring function can be used 
to quickly screen large databases of potential drugs in silico to identify 
molecules that are likely to bind to protein target of interest (see virtual 
screening). 
• Lead optimization – docking can be used to predict in where and in which 
relative orientation a ligand binds to a protein (also referred to as the 
binding mode or pose). This information may in turn be used to design 
more potent and selective analogs. 
• Bioremediation – Protein ligand docking can also be used to predict 
pollutants that can be degraded by enzymes. 
CANCER 
              Cancer is a group of diseases involving abnormal cell growth with the 
potential to invade or spread to other parts of the body. Not all tumors are 
cancerous; benign tumors do not spread to other parts of the body. 
Possible signs and symptoms include a lump, abnormal bleeding, prolonged 
cough, unexplained weight loss and a change in bowel movements. While 
these symptoms may indicate cancer, they may have other causes. Over 100 
types of cancers affect humans. Tobacco use is the cause of about 22% of 
cancer deaths. Another 10% is due to obesity, poor diet, lack of physical 
activity, and excessive drinking of alcohol. Other factors include 
certain infections, exposure to ionizing radiation and environmental 
pollutants. In the developing world nearly 20% of cancers are due to infections 
such as hepatitis B, hepatitis C and human papilloma virus infection. These 
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factors act, at least partly, by changing the genes of a cell. Typically many 
genetic changes are required before cancer develops. 
Definition 
              Cancers are a large family of diseases that involve abnormal cell 
growth with the potential to invade or spread to other parts of the body. They 
form a subset of neoplasms. A neoplasm or tumor is a group of cells that have 
undergone unregulated growth and will often form a mass or lump, but may 
be distributed diffusely. All tumor cells show the six hallmarks of cancer. 
These characteristics are required to produce a malignant tumor. They 
include: Cell growth and division absent the proper signals, Continuous 
growth and division even given contrary signals, Avoidance of programmed 
cell death, Limitless number of cell divisions, Promoting blood vessel 
construction, Invasion of tissue and formation of metastases. The progression 
from normal cells to cells that can form a detectable mass to outright cancer 
involves multiple steps known as malignant progression 
 
FIG.3: DIVISION OF CANCER CELLS 
Cell cycle and Regulation4 
                 During cell cycle, each cell divides into two daughter cells having 
identical genetic material. Each of these cells may immediately re-enter a new 
cell-cycle or pass into a non-proliferative resting state. 
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FIG.4: CELL DIVISION 
               The growth and division of cells can be defined into four prominent 
phases of cell-cycle. These include: 
                  
 
FIG.5: PHASES OF CELL CYCLE 
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Signs and symptoms5 
             When cancer begins, it produces no symptoms. Signs and symptoms 
appear as the mass grows. The findings that result depend on the cancer's 
type and location. Many frequently occur in individuals who have other 
conditions. Cancer is a great imitator. Thus, it is common for people 
diagnosed with cancer to have been treated for other diseases, which were 
hypothesized to be causing their symptoms. People may become anxious or 
depressed post-diagnosis. The risk of people with cancer is approximately 
double in suicide. 
Local symptoms 
              Local symptoms may occur due to the mass of the tumor or its 
ulceration. Masses in breasts or testicles may produce observable lumps. 
Although localized pain may occur in advanced cancer, the initial swelling is 
usually painless. Some cancers can cause a buildup of fluid within the chest 
or abdomen. 
Systemic symptoms 
            General symptoms occur due to effects that are not related to direct or 
metastatic spread. These may include: fever, excessive fatigue and changes 
to the skin. Hodgkin disease, leukemias and cancer of the liver or kidney can 
cause a persistent fever. Some cancers may cause specific groups of 
systemic symptoms, termed paraneoplastic syndrome. Examples include the 
appearance of myasthenia gravis in thymoma and clubbing in lung cancer. 
Metastasis 
             Cancer can spread from its original site by local spread, lymphatic 
spread to regional lymph nodes or by hematogenous spread via the blood to 
distant sites, known as metastasis. When cancer spreads by a hematogenous 
route, it usually spreads all over the body. However, cancer 'seeds' grow in 
certain selected site only ('soil') as hypothesized in the soil and seed 
hypothesis of cancer metastasis. The symptoms of metastatic cancers 
depend on the tumor location and can include enlarged lymph nodes (which 
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can be felt or sometimes seen under the skin and are typically hard), enlarged 
liver or enlarged spleen, which can be felt in the abdomen, pain or fracture of 
affected bones and neurological symptoms. 
Prevention6 
Cancer prevention is action taken to lower the risk of getting cancer. 
This can include maintaining a healthy lifestyle, avoiding exposure to known 
cancer causing substance, and taking medicines or vaccines that can prevent 
cancer from developing. 
Screening 
           Unlike diagnostic efforts prompted by symptoms and medical signs, 
cancer screening involves efforts to detect cancer after it has formed, but 
before any noticeable symptoms appear. This may involve physical 
examination, blood or urine tests or medical imaging. Cancer screening is not 
available for many types of cancers. Even when tests are available, they may 
not be recommended for everyone.  
Universal screening or mass screening involves screening everyone. 
Selective screening identifies people who are at higher risk, such as people 
with a family history. Several factors are considered to determine whether the 
benefits of screening outweigh the risks and the costs of screening.  
Management:  
            Many treatment options for cancer exist. The primary ones 
include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted 
therapy and palliative care. Which treatments are used depends on the type, 
location and grade of the cancer as well as the patient's health and 
preferences. The treatment intent may or may not be curative. 
Anti-Cancer drugs7 
         The drugs which are used for the treatment of cancer are called as 
anti-Cancer drugs. It is also called as Anti-Neoplastic drugs. 
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Classification of drugs 
They are classified as, 
alkylating agent, anti-Metabolites, antibiotics, plant products, enzymes, 
hormone, immuno theraphy, mono clonal antibodies, radio therapeutic agents, 
cyto protective agents and miscellaneous 
Alkylating agent 
            Cylophosphamide, chlorambucil, mechlorethamine, ifosfamide, 
melphalan, busulfan, carmustine, lomustine, semustine, ethylenimine, 
thiotepa, Dacarbazine & procarbazine. 
Anti-Metabolites 
             Cytarabine, fluorouracil, floxuridine, capecitabine, 6-thioguanine, 
mercaptopurine, fludarbine, pentostatin, cladribine, Methotrexate & 
azathioprine. 
Antibiotics 
        Doxorubicin, daunorubicin, idarubicine, bleomycin sulfate, mitomycin C, 
actinomycin D & mithramycin 
Plant products 
         Vincristine, vinblastine, vinorelbine, etoposide, Teniposide & paclitaxel 
Enzymes 
         L-Asparaginase, pegaspargase 
Hormones 
        Mitotane, megestrol, tamoxifen, letrozole, Dromostanolone & 
pipobroman 
Immuno theraphy 
         Interferon α-2a, interferon α-2b, interferon α-n3, aldesluekin, diftitox, 
Denileukin & Bacillus Calmette-Guerin(BCG) 
Introduction 
 
Department of Pharmaceutical Chemistry Page 12 
 
Monoclonal antibodies 
         Rituximab, Gemtuzumab & ozogamicin 
Radio therapeutic agents 
          Chromic phosphate P 32, sodium phosphate P 32, sodium iodide I 131, 
strontium 89 chloride & smarium SM 153 lexidronam 
Cyto protective agents 
          Mesna, Amifostine & dexrazoxane 
Miscellaneous 
          Cisplastin, carboplatin, hydroxy urea, hexamethylamine, altreamin, 
mitoxantrane, gallium nitrate, arsenic trioxide, bexavotene, sargramostim, 
Filgrastim & profimer sodium 
Mechanism of action8 
There are two main types of cell death: apoptosis and necrosis. 
Necrotic cell death is caused by gross cell injury and results in the death of 
groups of cells within a tissue. Apoptosis is a regulated form of cell death that 
may be induced or is preprogrammed into the cell (e.g. during development) 
and is characterized by speciﬁc DNA changes and no accompanying 
inﬂammatory response.  
It can be triggered if mistakes in DNA replication are identiﬁed. Loss of 
this protective mechanism would allow mutant cells to continue to divide and 
grow, thereby conserving mutations in subsequent cell divisions. Many 
cytotoxic anticancer drugs and radiotherapy act by inducing mutations in 
cancer cells which are not sufficient to cause cell death, but which can be 
recognized by the cell, triggering apoptosis. 
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FIG.6: MECHANISM OF ACTION OF ANTI-CANCER DRUGS 
MICRO ORGANISMS 
   Microbes are tiny organism too tiny to see without a microscope yet 
they are rich on earth. They live everywhere like air, soil, rock, water, poles, 
deserts & deep-sea.Study of microorganisms is called Microbiology. Study of 
bacteria and viruses is called Bacteriology and virology 
respectively.Microorganisms play important role to humans and they 
contribute recycling other organisms and decomposition the waste 
products.Some further advantageous activities of microbes are: 
Use in food 
Microbes are used in baking, other food making processes and also 
used the fermentation process in the production of dairy products like cheese. 
Use in science 
Microbes are also vital tools in biotechnology, biochemistry, genetics 
and molecular biology. 
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Human digestion 
                The bacteria that live within the human digestive system supply to 
gut immunity, synthesizes vitamins and ferment complex indigestible 
carbohydrates. 
In medicines 
Microbes are used to make vaccines which can be stimulate the 
production of antibodies substances to make sure future defense against with 
unwanted microbes. 
Most important types of microbes are bacteria, viruses, fungi, protozoa 
Bacteria9 
Bacteria constitute a large domain of prokaryotic microorganisms. 
Typically a few micrometer in length, bacteria have a number of shapes 
including balls, commas, rods, cubes and spirals.These are very useful in 
many fields like preparation of antibiotics, in human digestion,in fermentation 
etc.But they are spread out many infectious disease and which are main 
reason for universal mortality. 
Some example for bacterial diseases are, gonorrhea, syhilis, anthrax, 
tuberculosis, cholera, typhoid, fever, pneumonia, tetanus 
Virus10 
 A virus is a small infectious agent that multiply only inside the 
living cells of   other organisms.These are among the smallest microbes than 
bacteria.It consists genes which are present in one or more molecules of DNA 
or RNA which surrounded by a protein coat. 
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FIG.7: TYPES OF VIRUS 
 
 
FIG.8: TYPES OF BACTERIA 
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Antimicrobials 
             An antimicrobial is an agent which kills  micro organisms or inhibits 
their growth.Anti-microbial can be classified into two types depends upon their 
function. Microbicidal which means antimicrobial agents that kill microbes 
while inhibit their growth are called biostatic. 
Mechanism of action of antibiotics11 
Different antibiotics have different modes of action, due to the nature of 
their structure and degree of affinity to certain target sites within bacterial 
cells.   
1. Cell wall synthesis 
2. Protein synthesis 
3. Cytoplasmic membrane permeability 
4. Nucleic acid synthesis 
5. Anti metabolic synthesis  
 
 
FIG.9: MECHANISM OF ACTION OF ANTIBIOTICS 
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Antibiotic resistance12 
Antibiotic resistance occurs when bacteria change in some way that 
reduces or eliminates the effectiveness of drugs, chemicals, or other agents 
designed to cure or prevent infections. The bacteria survive and continue to 
multiply causing more harm. Bacteria can do this through several 
mechanisms. 
FIG.10: ANTI-BIOTIC RESISTANCE 
 
SUBJECT INTRODUCTION 
ISATIN13, 14  
           Isatin(indoline-2,3-dione), is an indole derivatives (Ex: Indozoline, 
Fluvaisatin), possessing an indole nucleus with two chemically distinct cyclic 
carbonyl groups, keto and lactam.  
 
 
Isatin 
N
H
O
O
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MANNICH BASE15, 16 
A Mannich base is a beta-amino-ketone, is an end product in 
the Mannich reaction, is the condensation reaction in which the compound 
containing active hydrogen atom is allowed to react with formaldehyde and an 
NH-amine derivative. 
 
 
 
 
SCHIFF BASE17, 18 
              A Schiff base is a nitrogen analog of an aldehyde or ketone in which 
the C=O group is replaced by C=N-R group. It is usually formed by 
condensation of an aldehyde or ketone with a primary amine. 
 
 
 
 
 
 
      R-H    +      CH2O       + R NH
R
R
N R
RAldehyde 
or Ketone
   Formaldehyde
Secondary
  amines
Mannich base
R NH2 + R
R
O
R
R
N R
Primary 
amine
Aldehyde or 
Ketone
Schiff 
base
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LITERATURE REVIEW 
Saleh A. Bahashwan et al19, 2013 investigated a new series of poly fused 
pyrazolothienopyrimidine derivatives (2–14) were synthesized and their anti-
parkinsonism, hypoglycemic and anti-microbial activities were evaluated. Some of 
the newly synthesized compounds exhibited better pharmacological and biological 
activities than the reference controls with low concentrations. The structures of newly 
synthesized compounds were confirmed by chemical, elemental and spectroscopic 
evidences. The detailed synthesis, spectroscopic data, and pharmacological activities 
were reported. 
Sanjana Chandran et al20., 2017 investigated  the objective of the present study was 
to identify the proteome pattern, isolate and study the functions of selective proteins 
from Ferula asafoetida  root exudate using chromatographic techniques. The root 
exudate proteins were fractionated using ion-exchange and gel filtration 
chromatography. A range of bioactive protein fractions were then separated in 
sufficient quantity which is the focus of this study. Based on studies, here we report 
three main proteins with molecular weights 14 kDa, 27 kDa, and 39 kDa. The 
biological and pharmacological activities of both purified and unpurified proteins 
obtained were extensively studied to understand their significance. The study revelaed 
that 27 kDa protein interestingly stabilized trypsin activity in 24 h of time and 
retained about 64% of the enzyme activity. Analyses confirmed 40°C and pH 8.0 are 
the optimum temperature and pH respectively. The 39 kDa protein remarkably 
increased the activity of chymotrypsin and the 14 kDa protein showed anti-bacterial 
activity against Pseudomonas aeruginosa. Invariably all of the three purified proteins 
showed enhanced anti-oxidant activity. In conclusion, results here obtained suggested 
that the primary metabolites (proteins) in asafoetida are mainly responsible for its 
versatile biological and pharmacological activities. 
Areej M.Assaf et al21., 2013 reported Mercurialis annua L., Bongardia 
chrysogonum L., and Viscum cruciatum Sieb have been traditionally used by local 
herbalists in Jordan for the treatment of hematopoietic neoplasms.To determine the 
anti-cancer, anti-inflammatory and anti-microbial potentials of the three extracts 
against two of the most common hematopoietic malignancies in the Jordanian 
populations; Burkitt's lymphoma and multiple myeloma.The anti-cancer activity was 
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tested against the two cell lines (BJAB Burkitt's lymphoma and U266 multiple 
myeloma) using the MTT and trypan blue assays. The agar dilution assay was used to 
study the anti-microbial activity against gram-positive bacteria, gram-negative 
bacteria, anaerobic bacteria and yeast. The pro-inflammatory cytokines interleukin 
(IL) -1β, IL-8 and tumor necrosis factor-α (TNF-α) were measured in the pretreated 
cell lines using ELISA assay to determine the anti-inflammatory activity of Viscum 
cruciatum Sieb against the two cell lines. 
Dun-Jia  Wang  et  al22., 2010 proposed several new trifluoromethyl-1H-pyrazoles 
were prepared by reaction of hydrazine monohydrate with 1, 3-diketones. Their 
structures were confirmed by elemental analysis, IR, 1H NMR and EI-MS 
spectroscopy. The anti-microbial activities of the newly synthesized compounds were 
examined by disc diffusion method against Escherichia coli, Staphylococcus 
aureus, Pyricularia oryzae and Rhizoctnia solani. All the trifluoromethyl-1H-
pyrazoles exhibited a certain degree of anti-bacterial and anti-fungal activities. 
Larry L. Klein et al23., 2013 investigated isatins (1) are valuable intermediates for 
heterocyclic chemistry. Most of the common methods for their production are less 
than adequate when the number and lipophilicity of substituents on the targeted isatin 
are increased. Our group desired such molecules and identified an alternative method 
for their production. 
N
H
O
O
 
Isatin (1) 
Nikolai M.Evdokimov et al24., 2016 proposed that in a search of small molecules 
active against apoptosis-resistant cancer cells, a series of isatin-based heterocyclic 
compounds were synthesized and found to inhibit proliferation of cancer cell lines 
resistant to apoptosis. The synthesis of these compounds involved a condensation of 
commercially available, active methylene heterocycles with isatin proceeding in 
moderate to excellent yields. The heterocyclic scaffolds prepared in the current 
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investigation appear to be a useful starting point for the development of agents to fight 
cancers with apoptosis resistance, and thus, associated with dismal prognoses. 
 
N
NH NH2
O
                                  
N
H
O
O
 
Isatin 3 hydrozone (2)                                          Isatin (3) 
 
Muhhammad Arshad et al25., 2017 reported  two new isatin derivatives (E)-N′-(1-
allyl-2-oxoindolin-3-ylidene)-4-methylbenzenesulfono-hydrazide(5) and (E)-N′-(1-
allyl-2-oxoindolin-3-ylidene)-4-chlorobenzenesulfono-hydrazide (6) were synthesized 
in good yields by adopting two component synthetic methodology.The structure 
elucidation was accomplished with the help of UV–vis., FT-IR and NMR (1H and13C) 
spectroscopic techniques. Suitable crystals were grown by slow evaporation method 
and structures were confirmed unequivocally with the help of single crystal X-ray 
diffraction analysis. Both isatin derivatives 5 and 6 exist in triclinic crystal packing 
having space group P-1. Crystal structures of both compounds showed that the 
geometries are stabilized by several intermolecular hydrogen bonds. Quantum 
mechanical calculations performed at density functional theory (DFT) level confirmed 
the experimental spectroscopic (UV–vis., FT-IR and 1H NMR) as well as X-ray 
diffraction results. Kinetic stability, reactivity, electrophilicity and nucleophilic 
behavior of both the derivatives was elaborated using frontier molecular orbitals 
(FMOs) and molecular electrostatic potential (MEP) analyses. Enzyme inhibition 
potential of both compounds were tested in vitro against Bacillus pasteurii urease and 
both compounds retarded the enzymatic activity with IC50 values of 39.46 ± 0.12 μM 
and 148.35 ± 0.16 μM respectively. 
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N
H
O
O OH  
Oxoindolin (4) 
Liang Ma et al26., 2013 investigated in a new series of mannich base of 1,3,4-
oxadiazole derivatives possessing 1,4-benzodioxan (6a–6ae) were synthesized and 
characterized by 1H NMR, ESI-MS and elemental analysis. The structure of 6b was 
further confirmed by single crystal X-ray diffraction. All these novel compounds were 
screened for their in vitro antioxidant activity employing 2, 2′-diphenyl-1-
picrylhydrazyl radical (DPPH), 2, 2′-azinobis (3-ethylbenzothiazoline-6-sulfonate) 
cationic radical (ABTS+ ) and ferric reducing antioxidant power (FRAP) scavenging 
assays. Due to the combination of 1, 4-benzodioxan, 1, 3, 4-oxadiazoles and 
substituted phenyl ring, most of them exhibited nice antioxidant activities. In all of 
these three assays mentioned above, compounds 6f and 6e showed significant radical 
scavenging ability comparable to the commonly used antioxidants, BHT and Trolox. 
Seven compounds with representative substituents or activities were selected for 
further assays in chemical simulation biological systems—inhibition of microsomal 
lipid peroxidation (LPO) and protection against 2, 2′-azobis (2-amidinopropane 
hydrochloride) (AAPH) (5) induced DNA strand breakage, in which 6f and 6e were 
demonstrated to be of the most potent antioxidant activities. 
NH2
NH
N
N
NH2
NHCH3 CH3
CH3 CH3
 
AAPH (5) 
Bhupendra Mistry et al27., 2017 reported a new mannich base series of piperazine 
linked berberine analogues was furnished in this study to screen the antioxidant and 
anticancer potential of the resultant analogues. Alkoxy group at a C-9 position of 
berberine was converted to hydroxyl functionality to enhance the ability of final 
scaffolds binding to the target of drug action mainly through hydrophobic effect, 
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conjugation effect, whereas mannich base functionality was introduced on the C-12 
position of berberine. Scaffolds were investigated for their free radical scavenging 
antioxidant potential in FRAP and DPPH assay, whereas tested to check their 
Fe+3 reducing power in ABTS assay. The radical scavenging potential of the final 
derivatives 4a–j was found excellent with IC50, <13 μg/mL and < 8 μg/mL in DPPH 
and ABTS assay, respectively, whereas some analogues showed significant 
Fe+3 reducing power with absorption at around 2 nm in the FRAP assay. Anticancer 
effects of titled compounds were inspected against cervical cancer cell line Hela and 
Caski adapting SRB assay, in which analogues 4a–j presented <6 μg/mL of IC50, and 
>30 of therapeutic indices, thus exerting low cytotoxic values against Malin–Darby 
canine kidney (MDCK) cell lines at CC50s >125 μg/mL. Hence, from the bioassay 
outcomes it can be stated that these analogues are dual active agents as the scavengers 
of reactive oxygen species and inhibitors of the cancerous cells as compounds with 
halogen functional group have overall good pharmacological potential in assays 
studied in this research. Correct structure of the final compounds was adequately 
confirmed on the basis of FT-IR and 1H NMR as well as elemental analyses. 
Gheorghe Roman et al28., 2015 proposed the biological activity of mannich bases, a 
structurally heterogeneous class of chemical compounds that are generated from 
various substrates through the introduction of an amino methyl function by means of 
the mannich reaction, is surveyed, with emphasis on the relationship between 
structure and biological activity. The review covers extensively the literature reports 
that have disclosed mannich bases as anticancer and cytotoxic agents, or compounds 
with potential antibacterial and antifungal activity in the last decade. The most 
relevant studies on the activity of mannich bases as anti-mycobacterial agents, anti-
malarials, or antiviral candidates have been included as well. The review contains also 
a thorough coverage of anticonvulsant, anti-inflammatory, analgesic and antioxidant 
activities of mannich bases. In addition, several minor biological activities of mannich 
bases, such as their ability to regulate blood pressure or inhibit platelet aggregation, 
their anti-parasitic and anti-ulcer effects, as well as their use as agents for the 
treatment of mental disorders have been presented. The review gives in the end a brief 
overview of the potential of mannich bases as inhibitors of various enzymes or 
ligands for several receptors. 
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Aamir Ahmad et al29., 2017 investigated lawsone (6) is a known naphthoquinone dye 
from the henna plant Lawsonia inermis. Out of a series of four new ferrocene 
modified mannich bases of 1a, the 2-pyridyl derivative 2a was distinctly more active 
than its analogs 2b–d in breast, prostate and pancreatic cancer cells. 2a also exhibited 
greater anti-proliferative effects when compared with the known anticancer active 
mannich bases 1b and 1c in the androgen-receptor negative PC-3 prostate and Pgp-
expressing KB-V1/Vbl cervix carcinoma cell lines. Compound 2a reached sub-
micromolar activities in these aggressive cancer cells and, thus, features a promising 
drug candidate for the efficient treatment of hormone- or multidrug-resistant cancer 
types. 
O
OH
O  
Lawsone (6) 
Maria susai Boobalan et al30., 2014 reported the antioxidant active mannich base 1-
[anilino (phenyl) methyl] pyrrolidine-2,5-dione (APMPD) have been synthesized and 
its FT-IR and FT-Raman vibrational spectra were recorded within the region of 
4000 cm−1, 50 cm−1 respectively. The molecular geometric parameters of APMPD 
have been computed using HF and DFT model theories. The energies of APMPD are 
calculated for all the eight possible conformers using B3LYP method at 6-311++G (d, 
p) basis set. From the computational results, the M1 conformer was identified as the 
most stable conformer of APMPD. The stable conformer was compared with 
experimental crystal geometry, which again fortifies the results of conformer analysis. 
The fundamental vibrations of the molecule are assigned according to the 
characteristic region and the literature report. The predicted highest occupied 
molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energy 
gap provide vivid idea on charge transfer behavior of APMPD. The molecular 
electrostatic potential (MEP) and Mulliken charge analysis indicate the feasible 
electrophilic and nucleophilic reactive sites on APMPD. The thermodynamic 
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properties (heat capacity, entropy, and enthalpy) of the title compound at various 
temperatures are calculated in gas phase. 
Poul Erik Hansen et al31., 2016 proposed mannich bases of 2-Hydroxy-3, 4, 5, 6-
tetrachlorobenzene are chosen as an exemplary case for tautomeric mannich bases. 
Molecular structures are calculated. OH stretching frequencies are rationalized based 
on DFT calculations. Intrinsic deuterium isotope effects on 13C chemical shifts in the 
M-form are estimated based on OH bond lengths. The observed deuterium isotope 
effects on 13C chemical shifts are demonstrated to be largely of equilibrium type 
except at ambient temperatures. 
Gilish Jose et al32., 2017 reported  the synthesis and biological evaluation of a new 
series of pyrrolo [3, 2-c] pyridine Mannich bases (7a-v). The mannich bases were 
obtained in good yields by one-pot three component condensation of pyrrolo [3, 2-c] 
pyridine scaffold (6a-c) with secondary amines and excess of formaldehyde solution 
in AcOH. The chemical structures of the compounds were characterized by 1H 
NMR, 13C NMR, LC/MS and elemental analysis. Single crystal X-ray diffraction has 
been recorded for compound 7k ([C23H29ClN4]+2, H2O). The in vitro antimicrobial 
activities of the compounds were evaluated against various bacterial and fungal 
strains using agar diffusion method and broth micro dilution method. 
Compounds 7e, 7f, 7r, 7t, and 7u were showed good gram-positive antibacterial 
activity against S. aureus, B. flexus, C. sporogenes and S. mutans. 
Furthermore, in vitro anti-mycobacterial activity was evaluated against 
Mycobacterium tuberculosis H37Rv (ATCC 27294) using MABA. Compounds 7r, 7t, 
and 7u were showed good anti-tubercular activity against Mtb (MIC ≥6.25 μg/mL). 
Among the tested compounds, 1-((4-chloro-2-(cyclohexylmethyl)-1H-pyrrolo [3, 2-c] 
pyridin-3-yl) methyl) piperidine-3-carboxamide (7t) was showed excellent anti-
mycobacterial activity against Mtb (MIC <0.78 μg/mL) and low cytotoxicity against 
the HEK-293T cell line (SI >>25). Molecular docking of the active compounds 
against glutamate racemase (MurI) and Mtb glutamine synthetase were explained the 
structure-activity observed in vitro. 
A.A.Kulkarni et al33., 2017 investigated a series of various schiff's and mannich base 
derivatives (N1–2 & ND1–6) of Lamotrigine (7) with (8) and substituted isatin were 
synthesized to get more potent anticonvulsant agents. The starting material for the 
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synthesis of various new schiff's and mannich base derivatives was isatin (1H-indole- 
2, 3-dione) which in turn was prepared from substituted isonitrosoacetanilide using 
aniline. Lamotrigine reacts with isatin & substituted isatin gave Schiff's bases (N1–2) 
which on reaction with various secondary amines (dimethylamine, diethylamine, 
morpholine) produced Mannich bases (ND1–6). The structures of newly synthesized 
compounds were characterized by using TLC, UV, FT-IR, 1HNMR and studied for 
their anticonvulsant activity. Anticonvulsant activity of all the derivatives was 
evaluated by MES method using phenobarbitone sodium & lamotrigine as standard 
drugs and % reduction of time spent by animals in extension, flexion, clonus, and 
stupor phase were noted. Compounds ND-4 and ND-6 showed significant 
anticonvulsant activity when compared with that of standard drugs. The remaining all 
compounds show moderate activity. Biological activity data of the synthesized 
derivatives revealed that, the synthesized derivatives are good anticonvulsant agents 
as compared to lamotrigine. 
 
N
H
O
O
                         
Cl Cl
N N
N
NH2
NH2  
Isatin (7)                                          Lamotrigine (8) 
 
Neelima et al34., 2016 reported schiff base metal complexes are well-known to 
intercalate DNA. The La (III) complexes have been synthesized such that they hinder 
with the role of the topoisomerases, which control the topology of DNA during the 
cell-division cycle. Although several promising chemotherapeutics have been 
developed, on the basis of Schiff base metal complex DNA intercalating system they 
did not proceed past clinical trials due to their dose-limiting toxicity. Here in,we 
discuss an alternative compound, the La (III) complex, [La (L1)2Cl3]. 7H2O based on a 
schiff base ligand 2, 3-dihydro-1H-indolo-[2, 3-b]-phenazin-4(5H)-ylidene) 
benzothiazole–2-amine (L1), and report in vitro cell studies. Results of antitumor 
activity using cell viability assay, reactive oxygen species (ROS) generation and 
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nuclear condensation in PC-3 (Human, prostate carcinoma) cells show that the metal 
complex is more potent than ligand. La (III) complexes have been synthesized by 
reaction of lanthanum (III) salt in 1:2 M ratio with ligands L1 and 3-
(ethoxymethylene)-2, 3-dihydro-1H-indolo [2, 3-b]-phenazin-4(5H)-ylidene) 
benzathiazole-2-amine (L2) in methanol. The ligands and their La (III) complexes 
were characterized by molar conductance, magnetic susceptibility, elemental 
analyses, FT–IR, UV–Vis, 1H/13C NMR, thermogravimetric, XRD, and SEM analysis. 
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RESEARCH OBJECTIVES 
Nitogen atom containing analogues possess significant 
pharmacological activities. Various hetero cyclic nucleuses containing 
nitrogen as a hetero atom such as Indole, Imidazole, Benztriazole, 
Benzoxazole, Triazole, Tetrazole, and Benzimidazole possess varied 
pharmacological activities. Imidazole moiety is a versatile lead molecule. It is 
nitrogen containing heterocyclic ring which possess wide range of biological 
activities such as anti-bacterial, anti-cancer, anti-tubular, anti-fungal, 
analgesic and anti-HIV activities. 
Among, the various synthetic products, the first choice of selection of 
nucleus in our current research work are isatin. Isatin nucleus have attracted 
the attention of medicinal chemists due to their wide range of biological 
activities like as anti-microbial, anti-cancer, anti-convulsant activity and acts 
as a anxiogenic, sedative and potent antagonist on atrial natriuretic peptide 
receptors in In-vitro. Isatin derivatives reported exhibit interesting 
pharmacological activities. The work was planned to perform that isatin was 
substituted by benzylamine at C-3 position to produce Benzylimino-isatin. The 
Benzylimino-isatin was substituted by various secondary amines at N-1 
position to produce Benzylimino-isatin Mannich bases, exhibits interesting 
pharmacological activities. 
The present study is aimed to carry out the synthesis of Benzylimino-
isatin Mannich base derivatives. For newer derivatives, Benzylimino-isatin as 
lead molecule by combining several secondary amines followed by 
formaldehyde will be synthesized as per literature method. Then, structures 
will be assigned by FT-IR and 1H NMR analysis. Further, the compounds are 
evaluated for biological activities such as anti-cancer and anti-microbial 
activities.  
In this aim, our current research work was initiated. 
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PLAN OF THE WORK 
Isatin nucleus is a versatile lead molecule and has attracted the 
attention of medicinal chemists and has wide range of biological activities 
such as anti-microbial, anti-cancer, anti-convulsant activity and acts as an 
anxiogenic, sedative and potent antagonist on atrial natriuretic peptide 
receptors in in-vitro. Isatin derivatives reported exhibit interesting 
pharmacological activities.  
On the basis of these considerations, and in continuation to the 
previous efforts of our laboratory team in the area of synthesis of anti 
proliferative agents as well as antibacterial agents  
The plan of this thesis were 
1. To manually design the synthetic compounds bearing benzylimino-
isatin scaffold. 
2. The above designed compounds subjected to docking study by the 
way using Molegro Virtual Docker (MVD) 
3. To select the compounds based on the best docking scores for further 
studies. 
4. To synthesize of benzylimino-isatin Mannich bases by using specific 
reagents and conditions. 
5. To characterize the newly synthesized compounds by means of their 
FT-IR and 1H NMR. 
6. To evaluate anti-microbial activity by disc diffusion method and well 
diffusion method and In vitro anti cancer activity against HeLa cancer 
cell line.  
N
O
N
R"   
Benzylimino-isatin Lead Compound
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SCHEME OF THE WORK 
          The scheme of the work deals with the synthesis of Benzylimino-isatin 
Schiff base and Benzylimino-isatin mannich base. 
 
N
H
O
O
+ NH2
                       EtOH Glacial acetic acid,reflux for 
8-9 hrs
N
H
N
O
Isatin Benzylamine
Benzylimino-isatin 
(1)
HCHO,Magnetic stirring                      MeOH
N
N
O
N
R1 R
2
Benzylimino-isatin mannich 
base
(2)
+ NH
R2
R1
R”= Dimethylamine 
        Diphenylamine 
        Piperazine 
        1-Methyl piperazine 
        Morpholine 
        Pthalimide    
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MATERIALS AND METHODS 
 
Software used in docking study 
The docking study was performed using Molegro Virtual Docker 
Evaluation Version (MVD 2013.6.0), which focused on molecular docking 
simulations 
Chemicals 
           All the chemicals used were analytical grade and were purchased from 
UNIVERSAL SCIENTIFIC APPLIANCES in Madurai. 
TABLE 1: Company name of the chemicals used in synthesis. 
S.NO CHEMICALS COMPANY NAME 
1. Isatin Sisco Research Laboratory 
2. Benzylamine High Purity Laboratory Chemicals 
3. Glacial acetic acid Fisher Scientific 
4. Dimethlyamine Loba Chemie 
5. Piperazine HiMedia Laboratories 
6. Pthalimide Santai Labs 
7. Diphenylamine Sisco Research Laboratory 
8. 1-Methly piperazine Spectrochem 
9. Morpholine Spectrochem 
10 Formaldehyde Sai Chemicals 
11. Ethanol Sisco Research Laboratory 
12. Methanol Molychem 
13. Chloroform Sisco Research Laboratory 
14. DMSO Fischer inorganics & aromatics Ltd 
15. Ethyl acetate Chem India Petrochems 
16. Hexane Roshan Chemical Industry 
17. Benzene Alpha Chemika 
18. Pet. ether Lab-Chem  Corporation 
19. Silica gel G Thomas baker 
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Instruments 
Infra-red spectrophotometer 
IR spectra were measured using SHIMADZU IR TRACER-100 IR 
spectrophotometer at IRC, Kalasalingam University, Srivilliputtur, 
Virudhunagar (DT). 
Nuclear magnetic resonance spectrophotometer 
1H NMR spectra was measured at Indian Institute of Science, 
Bangalore using SHIMADZU-400 instrument by CDCl3 as solvent. 
TABLE 2: Instruments and its model 
S.NO INSTRUMENT MODEL 
1. Digital balance ELB 300 SHIMADZU 
2. Magnetic stirrer MCS 66 
3. Rota vaccum evaporater RVO 400 
4. Melting point apparatus M-565 
5. FT-IR     Spectrophotometer IRTRACER-100 SHIMADZU 
6. 1H-NMR Spectrometer SHIMADZU-400 
7. MTT Assay reader Bio-Rad-680 
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EXPERIMENTAL METHODS 
DOCKING STUDY 
Reductase enzyme (PDB Code 1kf6) was retrieved from Brookhaven 
protein data bank. The docking study was performed using Molegro Virtual 
Docker Evaluation Version (MVD 2013.6.0), which focused on molecular 
docking simulations. While performing molecular docking, both the protein 
and ligand molecules were imported into the workspace. All the 
crystallographic water molecules were removed from the protein during import 
process. Further, protein and ligands were subjected to molecules 
preparation. The option to detect cavities in the preparation window was used 
to identify cavities within the enzyme 1kf6. During this computational 
procedure, maximum numbers of cavities were fixed to 10, grid resolution 
0.80 Å and probe size 1.2 Å; while the other parameters were set as default. 
The objective of protein preparation was to remove errors like bond order, 
bond position, explicitly hydrogen, flexible torsions etc.  
 
FIG.11: PROTEIN STRUCTURE OF 1KF6 
                While performing docking, the binding radius, grid resolution and 
maximum iterations parameters were set to 15 Å, 0.3 Å and 2,000 
respectively. The docking algorithm was set to simplex evolution population 
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size 50, RMSD thresholds 1.00 Å for cluster similar poses, and RMSD 
threshold 1.00 Å for ignoring similar poses (for multiple runs only), and 5 
independent runs were conducted, each of these runs returned to a single 
final solution (pose). Only negative lowest-energy representative cluster 
returned from each of them after completion of docking and similar poses 
were removed keeping the best scoring one. The clusters were ranked 
through comparison of the conformation of the lowest binding energy in each 
cluster. The first lowest binding free energy pose was selected for the analysis 
of the docking results and the other best docking complex also was analyzed 
for various intermolecular interactions. In the beginning, a total of five different 
cavities with different surface area and volume were mapped in E. coli Quinol-
Fumarate Reductase with Bound Inhibitor HQNO enzyme (1kf6) using the 
option detect cavity in MVD software. The volume and surface area of these 
cavities, Cavity 1 had highest volume (6637.06 Å3) along with largest surface 
area (18324.5 Å2).  
 
FIG.12: ENZYME OF 1KF6 SHOWING ALL FIVE CAVITIES AS 1,2,3,4   
AND 5. 
The docking score of the interaction between the active site of enzyme 
1kf6 and ligand molecules (IM1 - 20) has been depicted in Table 3.  
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N
O
N
R"  
Table 3: Docking Scores of benzylimino-isatin Mannich bases (Compound 
IM1 - 20) in the cavity of 1kf6 enzyme: 
Com. 
Code R” 
Mol-dock 
score 
Re-rank 
score 
H-bond 
score 
IM1 N
CH3
CH3
 
-146.225 -105.988 -3.693 
IM2 N
C2H5
C2H5
 
-121.342 -109.877 -2.142 
IM3 N
C6H5
C6H5
 
-183.245 -140.876 -1.402 
IM4 N NH
 
-167.199 -123.731 -3.887 
IM5 N N-CH3
 
-177.219 -129.985 -2.241 
IM6 N N-CH2-C6H5
 
-138.142 -117.346 -1.187 
IM7 N N
Cl  
-126.763 -107.934 -1.754 
IM8 N N Cl
 
-129.543 -112.347 -1.564 
IM9 N N
OCH3  
-110.654 -103.741 -0.942 
Materials and Methods 
 
Department of Pharmaceutical Chemistry Page 36 
 
IM10 N N OCH3 -112.384 -106.273 -1.046 
IM11 N N
CF3  
-98.483 -78.285 -0.282 
IM12 N CH3
 
-132.482 -112.392 -1.842 
IM13 
N
CH3  
-137.158 -107.384 -1.743 
IM14 N Cl
 
-121.354 -102.387 -1.372 
IM15 N
Cl  
-129.475 -99.452 -1.492 
IM16 N OCH3
 
-84.453 -71.564 -0.995 
IM17 
N
OCH3  
-104.264 -93.657 -1.548 
IM18 N
 
-85.375 -76.457 -0.578 
IM19 N O
 
-186.228 -135.796 -1.511 
IM20 N
O
O
 
-143.335 -114.225 -2.298 
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SYNTHESIS 
Step 1 
Synthesis of benzylimino-isatin [(3Z)-3-(benzylimino)-1, 3-dihydro-2H-
indol-2-one] (IS1): 
           Indole-2, 3-dione (isatin 0.001 mole) was dissolved in ethanol (30 mL) 
in a 250 ml round bottomed flask fitted with a condenser. Benzylamine (0.001 
mole) was dissolved in ethanol (10 mL) added to the mixture, followed by 3-4 
drops of glacial acetic acid. The reaction mixture was heated under reflux for 
8-9 hrs. The precipitate formed was filtered, recrystallized from ethanol and 
dried at hot air oven.The purity of the product was ascertained by TLC and the 
Rf value is 0.6271.Finally,the obtained titled compound is [(3Z)-3-
(benzylimino)-1, 3-dihydro-2H-indol-2-one]. 
N
H
O
O
+ NH2
                 Ethanol Glacial acetic acid, 8-9 hrs in 
reflux 
N
H
N
O
Isatin Benzylamine
(3Z)-3-(benzylimino)-1,3-dihydro-2H-indol-2-one
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Step 2 
Synthesis of benzylimino- isatin mannich bases 
General procedure 
           The above synthesized [(3Z)-3-(benzylimino)-1, 3-dihydro-2H-indol-2-
one] (0.01 mole) was dissolved in methanol (10 mL) and add appropriated 
secondary amines separately (0.01 mole), then add formaldehyde (0.01 mole) 
(37%) was added to the mixture with stirring. The stirring was held by 
magnetic stirrer continued for 3h and then it was left at room temperature for 
24h. The precipitate was collected and recrystallized from methanol and dried 
at hot air oven. The purity of the product was ascertained by TLC. Finally, the 
titled compounds was obtained and characterized by spectral datas. 
 
N
H
N
O
Benzylimino-isatin
+
HCHO,Magnetic stirring
          
CH3OH
N
N
O
N
R2
R1
Benzylimino-isatin mannich base
NH
R2
R1
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TABLE: 4 Synthesized compounds 
S.No Compound code R’’ 
IUPAC name of the synthesized 
compounds 
 
1. 
 
IM1 
N
CH3
CH3
 
[(3Z)-3-(benzylimino)-1-[(dimethylamino) 
methyl]-1, 3-dihydro-2H-indol-2-one]. 
 
2. 
 
IM3 
N
C6H5
C6H5
 
[(3Z)-3-(benzylimino)-1-[(diphenylamino) 
methyl]-1, 3-dihydro-2H-indol-2-one]. 
 
3. 
 
IM4 
N NH
 
[(3Z)-3-(benzylimino)-1-[(piperazin-1-yl 
methyl)-1, 3-dihydro-2H-indol-2-one]. 
 
4. 
 
IM5 
N N-CH3
 
[(3Z)-3-(benzylimino)-1-[(4-
methylpiperazin-1-yl) methyl]-1,3-dihydro-
2H-indol-2-one]. 
 
5. 
 
IM19 
N O
 
[(3Z)-3-(benzylimino)-1-[(morpholin-4-yl 
methyl)-1,3-dihydro-2H-indol-2-one]. 
 
6. 
 
IM20 
N
O
O
 
2-{[(3Z)-3-(benzylimino)2-oxo-2,3-
dihydro-1H-indol-1yl)methyl]}-1H-
isoindole-1,3(2H)-dione. 
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BIOLOGICAL EVALUATION 
IN VITRO STUDIES 
 Anti-microbial activity 
 Anti-cancer activity 
Invitro anti-microbial studies: 
a) Well diffusion method 
b) Disc diffusion method 
Media preparation:  
Bacterial medium (Muller Hinton Agar) 
           36 g of Muller Hinton media (Hi-Media) was mixed with distilled water 
and then sterilized in autoclave at 15 LB pressure for 15 minutes. The 
sterilized media were poured into petri dishes. The solidified plates were 
pored with 6 mm dia.cork borer. The plates with wells were used for the 
antibacterial studies. 
Test against standard controls 
Commercially available antibiotic disc ciprofloxacin (10 µg) and was 
used as standard control for the entire test microorganism.  
Bacterial inoculums:  
            Bacterial inoculums were prepared by inoculating a loopful of test 
organisms such as E.coli, B.subtilis, P.aeruginosa and  S.aureus  in 5 mL 
nutrient broth and incubated at 37ºC for 5 to 8hrs till a moderate turbidity was 
developed. The turbidity was matched with 0.5 Mc Farland standard (WHO 
drug information, 1993) and the culture was diluted with sterile distilled water 
if necessary which corresponds to the cell density of 1.5 x 108 (CFU/mL). 
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FIG.13: LAMINAR AIR FLOW CHAMBER 
Well diffusion method36 
            Antibacterial of the synthetic compound was tested using well diffusion 
method. The prepared culture plates were inoculated with different selected 
strains of bacteria using streak plate method. Wells were made on the agar 
surface with 6mm cork borer. The synthesized compounds were loaded into 
the well using sterile syringe. The plates were incubated 24 hours at 37 ± 2ºC 
bacterial plates. The plates were observed for inhibition zone formation 
around the well. The zone of inhibition was calculated by measuring the 
diameter of the inhibition zone around the well (in mm) including the well 
diameter. The various concentration of benzylimino-isatin (IS1) and 
benzylimino-isatin Mannich base derivatives (IM1, IM3, IM4, IM5, IM19 & 
IM20) were used throughout the study. The derivatives of 
5µg/0.1mL,10µg/0.1mL,25µg/0.1mL,50µg/0.1mL & 100µg/0.1 mL were tested 
against 4 different bacterial pathogens such as Bacillus subtilis, 
Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli for their 
antimicrobial activity. It was demonstrated by well diffusion assay and 
reported. 
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Disc diffusion method37 
Principle 
           Paper discs impregnated with specific antibiotics or the test substances 
were placed on the surface of the Muller Hinton agar medium inoculated with 
the target organisms, which was recommended for the diffusion of 
antimicrobial agents as described in NCCLS approved standard. The plates 
incubated and the zones of inhibition around each disc were measured. 
Procedure 
           Petri dishes were prepared with a base layer of Mueller Hinton agar. At 
twenty-four hours culture of selected bacteria like Bacillus 
subtilis,Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia 
coli were mixed with physiological saline solution and the turbidity was 
corrected by adding sterile physiological saline until a Mc Farland turbidity 
standard of 0.5 (108 CFU/mL). Afterwards, a top layer of Mueller Hinton agar 
inoculated with 0.2% microbial suspension was poured over the petri dishes. 
Sterile filter discs (6 mm in diameter) were impregnated with benzylimino-
isatin (IS1) and various derivatives of benzylimino-isatin mannich bases such 
as IM1, IM3, IM4, IM5, IM19 & IM20 (5, 10, 25, 50, 100 µg/0.1mL) dissolved in 
DMSO and placed on the inoculated plates. Ciprofloxacin was used as 
control. The plates were incubated at 35ºC for 18 hours microbial growth 
inhibition was determined as the diameter of the inhibition zones around the 
discs and reported. 
 Invitro anti-cancer studies 
           Anti-cancer activity was studied for the various concentrations 
(10µg/1mL, 50µg/1mL, 100µg/1mL, 250µg/1mL & 500µg/1mL) of benzylimino-
isatin (IS1) and benzylimino-isatin Mannich base derivatives (IM1, IM3, IM4, 
IM5, IM19 & IM20) against cervical (HeLa) cancer cells. 
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 Procedure35   
             The HeLa cells were trypsinized and seeded into 96-wellplates (1000 
cells per well) containing Iscove’s Modified Dulbecco’s medium with 10% 
serum, with the medium being changed according to the experimental design 
after 24 h. 
 
FIG.14: MTT assay 96 well plates 
The cells were treated with various concentrations (10µg/1mL, 
50µg/1mL,100µg/1mL,250µg/1mL & 500µg/1mL) of synthetic chemical such 
as benzylimino-isatin (IS1) and benzylimino-isatin Mannich base derivatives 
(IM1, IM3, IM4, IM5, IM19 & IM20) and incubated at 37ºC in a humidified 
incubator with 5% CO2 . After 24 h of incubation, 10µL of MTT was added to 
each well, and the plates were incubated for a further 4 hrs. Following 
incubation the formazan crystals were dissolved in 100 mL of dissolving buffer 
and the absorbance read at 595 nm using a plate reader (Bio-Rad, Model 
680). 5FU is used as standard.IC50 values were determined further based on 
a 50% reduction in cell viability. The cells were stained with trypan blue and 
live cells were enumerated in order to determine % growth inhibition. The 
experiments were done in triplicates. The morphology changes on cancer 
cells observed under phase contrast microscope. 
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CHARACTERIZATION 
IS1 
   Structure: 
N
H
N
O
 
Compound code            :   IS1 
IUPAC name                  : (3Z)-3-(benzylimino)-1, 3-dihydro-2H-indol-2-one 
Colour                             :  Brown 
Melting point                 :  75-78ºC 
Molecular formula           :  C15H12N2O 
Molecular weight           :  236.26 
Percentage yield               : 70.75% 
Rf value                            : 0.6271 
IR   (KBr, cm-1)                : 1024, 1618, 1716, 2819, 2881, 3199 
NMR (400 CDCl3) δ [ppm]  :  4.73 (s, 2H, CH2 - benzyl) 
                                              7.00-7.11 (m, 5H, ArH of benzyl) 
                                              7.25-7.41 (m, 4H, ArH of Isatin) 
                                              7..89 (s, 1H,NH of isatin,D2O Exchangable) 
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IM1 
    Structure: 
N
N
O
N
CH3
CH3  
Compound code        :  IM1 
IUPAC name                   :  (3Z)-3-(benzylimino)-1-[(dimethylamino) methyl]-
       1,3-  dihydro-2H-indol-2-one 
Colour                             : Dark brown 
Melting point              : 80-90ºC 
Molecular formula         : C18H19N3O 
Molecular weight             : 293.36 
Percentage yield             : 60.76% 
Rf value                            : 0.7673 
IR   (KBr, cm-1)             : 1053, 1610, 1716, 2870, 2941, 3059 
NMR (400 CDCl3) δ [ppm]  : 2.72 (s, 6H (CH3)2) 
  3.63 (s, 2H, N- CH2- N) 
  4.71(s,2H,CH2 of benzyl) 
  7.05-7.19 (m, 5H, ArH of benzyl) 
  7.39-7.85 (m,4H, ArH of Isatin) 
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IM3 
  Structure: 
N
N
O
N
 
Compound code      : IM3 
IUPAC name            : (3Z)-3-(benzylimino)-1-[(diphenylamino)methyl]- 
                                              1,3-dihydro-2H-indol-2-one 
Colour                               : Brown 
Molecular formula           : C28H23N3O 
Molecular weight              : 417.50 
Percentage yield               : 76.78%  
Rf value                         :  0.5627 
IR   (KBr, cm-1)                : 1018, 1651, 2831, 2945 
NMR (400 CDCl3) δ [ppm] : 3.81 (s, 2H, N- CH2-N) 
  4.70 (s, 2H, CH2 of benzyl) 
  7.05-7.19(m, 5H, ArH of benzyl) 
  7.39-7.85 (m,4H, ArH of Isatin) 
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IM4 
   Structure: 
N
N
O
N
N
H  
Compound code        : IM4 
IUPAC name           : (3Z)-3-(benzylimino)-1-[(piperazin-1-yl methyl)-1, 
       3-  dihydro-2H-indol-2-one 
Colour                        : Pale yellow 
Melting point               : 70-76ºC 
Molecular formula          : C20H22N4O 
Molecular weight         : 334.41 
Percentage yield            : 73.12% 
Rf value                            : 0.7797 
IR   (KBr, cm-1)                  : 1051, 1610, 1718, 2804, 2879, 3057 
NMR (400 CDCl3) δ [ppm] : 2.50-2.92 (m, 10H, piperazinyl H) 
  4.15 (s, 2H, N-CH2-N) 
  5.32 (s, 2H, CH2 of benzyl) 
  7.00-7.20(m,5H,ArH of benzyl) 
  7.74-7.89 (m, 4H, ArH of Isatin) 
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IM5 
Structure: 
N
N
N O
N
CH3  
Compound code             : IM5 
IUPAC name             :  (3Z)-3-(benzylimino)-1-[(4-methylpiperazin-1yl)                          
        methyl]-1,3-dihydro-2H-indol-2-one 
Colour                              : Dark red 
Molecular formula           : C21H24N4O 
Molecular weight               : 348.44 
Percentage yield             : 90.76% 
Rf value                             : 0.9426 
IR   (KBr, cm-1)              : 1020, 2831, 2945 
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IM19 
Structure: 
N
N
O
N
O  
Compound code        : IM19 
IUPAC name                 : (3Z)-3-(benzylimino)-1-[(morpholin-4-yl methyl)- 
      1,3-dihydro-2H-indol-2-one 
Colour                           : Pale red 
Molecular formula        : C20H21N3O2 
Molecular weight            : 335.39 
Percentage yield           : 83.88% 
Rf value                           : 0.9787 
IR   (KBr, cm-1)                  : 1020, 1651, 2831, 2943 
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IM20 
Structure: 
N
N
O
N
O
O
 
Compound code              : IM20 
IUPAC name                  : (3Z)-3-(benzylimino)2-oxo-2, 3-dihydro-1H- 
       indol1yl)methyl]-1H-isoindole-1,3(2H)-dione 
Colour                             : Pale yellow 
Melting point                  : 70-79ºC 
Molecular formula         : C24H17N3O3 
Molecular weight             : 395.41 
Percentage yield              : 87.12% 
Rf value                          : 0.6235 
IR   (KBr, cm-1)                : 1060, 1610, 1707, 2895, 2954, 3489 
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RESULTS & DISCUSSION 
Docking studies of different benzylimino-isatin derivatives (IM1, IM2, 
IM3, IM4, IM5, IM6, IM7, IM8, IM9, IM10, IM11, IM12, IM13, IM14, IM15, 
IM16, IM17, IM18, IM19 & IM20) were performed successfully inside the 
highest volume cavity measure the affinity were Mol Dock, re-rank and H-
bond score of the above designed compounds with E. coli Quinol-Fumarate 
Reductase with Bound Inhibitor HQNO enzymes (1kf6). It facilitated us to 
identify relevant H-bond interaction (via H-bond score) that occurs between 
each ligand and the amino acid residues of the active site of enzyme in order 
to obtain conformations achieved with these molecules. Although the key 
moieties of all the compounds were similar but each individual compound 
showed interaction up to a variable extent.  
The best Docking Score of the compounds (table 5) were selected for 
the synthesis as well as biological evaluation, among various compounds, 
IM19 ([(3Z)-3-(benzylimino)-1-[(morpholin-4-ylmethyl)-1,3-dihydro-2H-
indol-2-one]) showed highest MolDock score (-186.228) as well as re-rank 
score (-135.796) as compared to the other benzylimino-isatin derivatives. 
While compound IM16 showed poor MolDock score (-84.453) as well as re-
rank score (-71.564) as compared with other Mannich bases of benzylimino-
isatin derivatives. Docking view, hydrophobic and steric interactions and 
secondary view of IM19 ([(3Z)-3-(benzylimino)-1-[(morpholin-4-ylmethyl)-
1,3-dihydro-2H-indol-2-one])  with 1kf6 enzyme have been shown in Figs. 
(15, 16 & 17) respectively.  
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Table. 5: Selected Docking Scores of compounds in the cavity 1 of 1kf6 
Enzyme 
Com. Code Mol-dock score Re-rank score H-bond score 
IS1 -136.065 -104.478 -3.179 
IM1 -146.225 -105.988 -3.693 
IM3 -183.245 -140.876 -1.402 
IM4 -167.199 -123.731 -3.887 
IM5 -177.219 -129.985 -2.241 
IM19 -186.228 -135.796 -1.511 
IM20 -143.335 -114.225 -2.298 
  
 
FIG.15: DOCKING VIEW OF LIGAND (IM19) AND PROTEIN (1KF6) 
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FIG.16: SECONDARY VIEW OF COMPOUND IM19 (GREEN COLOUR) 
WITH 1KF6 ENZYME HAVING PDB ID: 1KF6 (RED AS Α-HELICES AND 
BLUE AS Β-SHEETS) 
 
 
 
FIG.17: HYDROPHOBIC INTERACTIONS OF COMPOUND IM19 WITH 
1KF6 ENZYME SHOWING HYDROPHOBIC AND HYDROPHILIC 
SURFACES 
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SOLUBILITY DATA 
The title compounds of IS1 [(3Z)-3-(benzylimino)-1, 3-dihydro-2H-
indol-2-one)] were synthesized from isatin and benzylamine in the presence 
of glacial acetic acid/EtOH, reflux with 8-9 h, as reported literature. The 
Mannich bases of benzylimino-isatin IM1 ([(3Z)-3-(benzylimino)-1-
[(dimethylamino)methyl] -1,3-dihydro-2H-indol-2-one]), IM3 ([(3Z)-3-
(benzylimino)-1-[(diphenylamino) methyl]-1, 3-dihydro-2H-indol-2-one]), 
IM4 ([(3Z)-3- (benzylimino)-1- [(piperazin-1-yl methyl)-1, 3-dihydro-2H-
indol-2-one]), IM5([(3Z)-3- (benzylimino)-1- [(4-methylpiperazin-1-yl) 
methyl] -1,3-dihydro- 2H-indol-2-one]), IM19([(3Z)-3- (benzylimino)-1-
[(morpholin-4-ylmethyl) -1,3-dihydro-2H-indol-2-one]) and IM20 (2-{[(3Z)-
3-(benzylimino)2-oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole 
1,3(2H)-dione) were prepared by the reaction of benzylimino isatin Schiff 
bases IS1[(3Z)-3- (benzylimino)- 1,3-dihydro- 2H-indol-2-one)] with 
appropriate secondary amines in the presence of HCHO at room temperature. 
The solubility data of the synthesized compounds were posted on table 6. 
From the table all the compounds were freely soluble in ethanol, methanol 
and DMSO moreover all the synthesized compounds were insoluble in water, 
hexane and pet.ether.  
TABLE.6: SOLUBILITY DATA OF THE SYNTHESIZED COMPOUNDS 
S.    
No 
Com. 
Code 
Solvents 
MeO
H 
EtO
H CHCl3
Et. 
acetate Water Hexane 
Pet 
ether
DMS
O 
1. IS1 +++ +++ ++ + - - - ++ 
2. IM1 +++ +++ ++ + - - - ++ 
3. IM3 +++ +++ ++ + - - - ++ 
4. IM4 +++ +++ ++ + - - - ++ 
5. IM5 +++ +++ ++ + - - - ++ 
6. IM19 +++ +++ ++ + - - - ++ 
7. IM20 +++ +++ ++ + - - - ++ 
+++    Freely soluble; ++    readily soluble; +   Soluble; - Insoluble. 
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CHARACTERIZATION 
The structures of the targeted compounds were confirmed by the 
means of FT-IR, 1H NMR spectral data. The synthesized compounds IS1 
[(3Z)-3-(benzylimino)-1, 3-dihydro-2H-indol-2-one)] and IM1 [(3Z)-3-
(benzylimino)-1-[(dimethylamino) methyl]-1,3-dihydro-2H-indol-2-one], 
IM3 [(3Z)-3-(benzylimino)-1-[(diphenylamino) methyl]-1, 3-dihydro-2H-
indol-2-one], IM4 [(3Z)-3-(benzylimino)-1-[(piperazin-1-yl methyl)-1,3-
dihydro-2H-indol-2-one],IM5[(3Z)-3-(benzylimino)-1-[(4-methylpiperazin-
1-yl)methyl]-1,3-dihydro-2H-indol-2-one],IM19[(3Z)-3-(benzylimino)-1-
[(morpholin-4-yl methyl)- 1,3-dihydro-2H-indol-2-one] and IM20 [(2-{[(3Z)-
3-(benzylimino)2-oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole-
1,3(2H)-dione)] of benzylimino-isatin Mannich bases, IR spectra were 
showed peak at 1640 for the conformation of C=N (azomethine) and one 
intensive peak were showed at 1715 for the conformation of C=O (Ketone), all 
the compounds shows peaks at 2860 and 2840 for the conformation of 
Mannich bases N-CH2-N. 
The synthesized compound benzylimino-isatin IS1 [(3Z)-3-
(benzylimino)-1, 3-dihydro-2H-indol-2-one)] showed a singlet at 4.81 ppm 
which assigned for CH2 of C6H5-CH2. Multiplet shows at 7.0-7.14 which 
assigns 5H for aromatic ring for benzyl and multiplet shows 7.27-7.72 ppm 
which assign for aromatic ring for isatin and one singlet shows at 8.0 ppm 
which assign for NH proton for isatin.  
The synthesized compounds of benzylimino-isatin Mannich bases, all 
the compounds shows singlet at 4.81 ppm which assign for 2H proton for the 
CH2 of benzyl, one multiplet shows at 7.0-7.14 ppm which assign 5H for 
aromatic ring for benzyl and multiplet shows at 7.27-7.72 ppm which assign 
for 4H for isatin aromatic proton and one singlet at 4.03 shows 2H for N-CH2-
N of Mannich bases. 
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ANTIBACTERIAL ACTIVITY 
The antibacterial activities of synthesized compounds IS1 [(3Z)-3-
(benzylimino)-1, 3-dihydro-2H-indol-2-one)] , IM1 [(3Z)-3-(benzylimino)-1-
[(dimethylamino) methyl]-1, 3-dihydro-2H-indol-2-one], IM3 [(3Z)-3-
(benzylimino)-1-[(diphenylamino) methyl]-1, 3-dihydro-2H-indol-2-one], 
IM4 [(3Z)-3-(benzylimino)-1-[(piperazin-1-yl methyl)-1, 3-dihydro-2H-indol-
2-one], IM5 [(3Z)-3-(benzylimino)-1-[(4-methylpiperazin-1-yl) methyl]-1,3-
dihydro-2H-indol-2-one], IM19 [(3Z)-3-(benzylimino)-1-[(morpholin-4-yl 
methyl)-1,3-dihydro-2H-indol-2-one] and IM20 [2-{[(3Z)-3-(benzylimino)2-
oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole-1,3(2H)-dione] were 
evaluated by the determination of their zone of inhibition by using disc 
diffusion method as well as well diffusion method. A panel of gram-positive (S. 
aureus ATCC 6538, Bacillus subtilis ATCC 6633) and gram negative (E. coli 
ATCC 8739, Pseudomonas aeruginosa ATCC 9027) bacteria was used. The 
quinolone antibacterial agent ciprofloxacin was used as reference drug. 
Disc diffusion method 
The entire compound shows moderate antibacterial activity. 
Compounds IM3 [(3Z)-3-(benzylimino)-1-[(diphenylamino) methyl]-1, 3-
dihydro-2H-indol-2-one], IM4 [(3Z)-3-(benzylimino)-1-[(piperazin-1-yl 
methyl)-1, 3-dihydro-2H-indol-2-one] and IM20 [2-{[(3Z)-3-(benzylimino)2-
oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole-1,3(2H)-dione] were 
shows good activity about 19 mm  zone of inhibition at 100µg/0.1ml 
concentration in gram –ve bacteria (P. aeruginosa) while compare with 
standard fluoroquinolone antibacterial ciprofloxacin have 30 mm zone of 
inhibition at 100µg/0.1ML concentration in gram –ve bacteria (P. aeruginosa) 
as well as gram +ve bacteria (B. subtilis). The antibacterial results by disc 
diffusion method were posted at table 7.   
Well diffusion method: 
The Compounds IM3 [(3Z)-3-(benzylimino)-1-[(diphenylamino) 
methyl]-1, 3-dihydro-2H-indol-2-one], IM4 [(3Z)-3- (benzylimino)-1-
[(piperazin-1-yl methyl)-1, 3-dihydro-2H-indol-2-one] and IM20 [2-{[(3Z)-3-
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(benzylimino)2-oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole-1,3 
(2H)- dione] were shows good activity about 20 mm zone of inhibition at 
100µg/0.1ML concentration in gram –ve bacteria (P. aeruginosa) while 
compound 6 shows significant activity about 20mm zone of inhibition at 50 
µg/ml concentration in gram –ve bacteria (P. aeruginosa). The standard 
fluoroquinolone antibacterial ciprofloxacin have 30mm zone of inhibition at 50 
µg/ml concentration in gram –ve bacteria (P. aeruginosa) as well as gram +ve 
bacteria (B. Subtilis). The antibacterial results by well diffusion method were 
posted at table 8.   
 
TABLE.7: ANTIMICROBIAL ACTIVITY OF THE SYNTHESIZED 
COMPOUNDS BY DISC DIFFUSION METHOD 
 
S. 
No 
 
Com. 
Code 
Zone of inhibition (mm) 
S. aureus B. subtilis P.aeruginosa E. Coli 
25 50 100 25 50 100 25 50 100 25 50 100 
1. IS1 9 9 9 9 10 9 10 12 14 9 10 10 
2. IM1 9 11 13 10 10 14 10 12 13 9 9 11 
3. IM3 10 10 12 10 11 11 10 14 19 9 10 11 
4. IM4 9 9 9 11 14 14 11 12 19 9 9 11 
5. IM5 9 9 10 9 10 14 10 12 14 9 10 10 
6. IM19 11 11 12 10 14 12 9 10 15 9 9 11 
7. IM20 9 9 9 9 9 9 10 15 19 9 10 11 
8. Ciprofloxacin 20 (10 µg/ml) 30 (10 µg/ml) 30 (10 µg/ml) 20 (10 µg/ml) 
Concentration 25, 50, 100 µg/ml. 
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TABLE.8: ANTI-MICROBIAL ACTIVITY OF THE SYNTHESIZED 
COMPOUNDS BY WELL DIFFUSION METHOD 
S.No  Com. Code 
Zone of inhibition (mm) 
S. aureus B. subtilis P.aeruginosa E. Coli 
25 50 100 25 50 100 25 50 100 25 50 100
1. IS1 10 10 10 10 11 15 11 13 15 10 11 11 
2. IM1 12 12 13 11 15 10 10 20 20 10 10 12 
3. IM3 11 11 13 11 11 12 10 10 20 10 11 12 
4. IM4 10 10 10 12 15 15 12 13 20 10 10 12 
5. IM5 10 10 10 10 11 15 11 13 15 10 11 11 
6. IM19 12 12 13 11 15 13 10 20 20 10 10 12 
7. IM20 10 10 10 10 10 10 10 10 20 10 11 11 
8. Ciprofloxacin 20 (10 µg/ml) 
30 (10 
µg/ml) 30 (10 µg/ml) 
20 (10 
µg/ml) 
Concentration 25, 50, 100 µg/ml. 
 
WELL DIFFUSION METHOD 
 
 FIG.18: ZONE OF ANTI-MICROBIAL INHIBITION OF IM1 (100 µG/0.1 ML) 
AND IM2 (5, 10 & 25 µG/0.1 ML) AGAINST P.AERUGINOSA 
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FIG.19: ZONE OF ANTI-MICROBIAL INHIBITION OF IM2 (50 & 100 µG/0.1 
ML) AND IM3 (5 & 10µG/0.1 ML) AGAINST P.AERUGINOSA 
 
 
 
FIG.20: ZONE OF ANTI-MICROBIAL INHIBITION OF IM3 (25, 50 & 100 
µG/0.1 ML) AND IM4 (5µG/0.1 ML) AGAINST P.AERUGINOSA 
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FIG.21: ZONE OF ANTI-MICROBIAL INHIBITION OF IM4 (10, 25, 50 & 100 
µG/0.1 ML) AGAINST P.AERUGINOSA 
 
 
FIG.22: ZONE OF ANTI-MICROBIAL INHIBITION OF STANDARD 
(CIPROFLOXACIN-10 µG/ML) AND SOLVENT (DMSO) AGAINST E.COLI 
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FIG.23: ZONE OF ANTI-MICROBIAL INHIBITION OF IM2 (100 µG/0.1 ML) 
AND IM3 (5 & 10 µG/0.1 ML) AGAINST E.COLI 
 
 
FIG.24: ZONE OF ANTI-MICROBIAL INHIBITION OF IM2 (5 µG/0.1 ML) 
AND IS1 (50 & 100 µG/0.1 ML) AGAINST E.COLI 
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FIG.25: ZONE OF ANTI-MICROBIAL INHIBITION OF SOLVENT (DMSO) 
AND STANDARD (CIPROFLOXACIN-10µG/0.1 ML) AGAINST B.SUBTILIS 
          
 
 
 FIG.26: ZONE OF ANTI-MICROBIAL INHIBITION OF IM2 (25, 50 
&100µG/0.1 ML) AGAINST B.SUBTILIS 
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FIG.27: ZONE OF ANTI-MICROBIAL INHIBITION OF SOLVENT (DMSO) 
AND STANDARD (CIPROFLOXACIN-10µG/0.1 ML) AGAINST S.AUREUS 
 
 
FIG.28: ZONE OF ANTI-MICROBIAL INHIBITION OF IM1 (100 µG/0.1 ML) 
AND IM2 (5 & 10 µG/0.1 ML) AGAINST S.AUREUS 
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ANTICANCER ACTIVITY 
             The anticancer activity for synthesized compounds was performed in 
HeLa cell line by MTT assay method. The results of the synthesized 
compounds in the form of IC50 was posted at table 8.From the table 9, the 
compound IM3 [(3Z)-3-(benzylimino)-1-[(diphenylamino) methyl]-1, 3-
dihydro-2H-indol-2-one] and IM20 2-{[(3Z)-3-(benzylimino)2-oxo-2,3-
dihydro-1H-indol-1yl)methyl]}-1H-isoindole-1,3(2H)-dione has good 
activity about 0.327, 0.392 µg/ml respectively while other compounds shows 
moderate activity. 5FU used as standard and it have IC50 about 0.21 µg/ml. 
 
TABLE.9: IN VITRO CELL GROWTH INHIBITORY (IC50) VALUES OF THE 
SYNTHESIZED COMPOUNDS 
S.No Compound code IC50  (µg / mL) 
1. IS1 0.423 
2. IM1 0.426 
3. IM3 0.392 
4. IM4 0.417 
5. IM5 0.432 
6. IM19 NT 
7. IM20 0.327 
8. 5FU 0.21 
 
IC50 : Compound concentration required to inhibit tumor cell proliferation by 
50%. 
   NT:    Not tested 
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SUMMARY AND CONCLUSION 
Our   current   research work deals with manually designed, library of 
compounds (IM1-20) bearing benzylimino-isatin scaffold that performed 
docking study with E.coli Quinol-Fumarate Reductase with Bound Inhibitor 
HQNO enzyme (1kf6) [PDB code 1kf6] using Molegro Virtual Docker 
Evaluation version (MVD 2013.6.0) the  best compounds were selected based 
on their Moldock score in order to synthesis of benzylimino-isatin (IS1)([(3Z)-
3-(benzylimino)-1,3-dihydro-2H-indol-2-one)]) and benzylimino-isatin mannich 
base derivatives with isatin as a parent moiety. Benzylimino-isatin (IS1) ([(3Z)-
3-(benzylimino)-1,3-dihydro-2H-indol-2-one)])  and benzylimino-isatin mannich 
bases such as IM1 [(3Z)-3-(benzylimino)-1-[(dimethylamino) methyl]-1, 3-
dihydro-2H-indol-2-one], IM3 [(3Z)-3-(benzylimino)-1-[(diphenylamino) 
methyl]-1, 3-dihydro-2H-indol-2-one], IM4 [(3Z)-3-(benzylimino)-1-[(piperazin-
1-yl methyl)-1, 3-dihydro-2H-indol-2-one], IM5 [(3Z)-3-(benzylimino)-1-[(4-
methylpiperazin-1-yl) methyl]-1,3-dihydro-2H-indol-2-one], IM19 [(3Z)-3-
(benzylimino)-1-[(morpholin-4-yl methyl)-1,3-dihydro-2H-indol-2-one] & IM20 
[2-{[(3Z)-3-(benzylimino)2-oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole-
1,3(2H)-dione] were synthesized by the suitable experimental procedure.  
The synthesized compounds were characterized by melting point, 
solubility and subjected to various common analytical techniques like TLC, 
FT-IR and 1H NMR and it is confirmed  by means of their FT-IR and 1H NMR 
spectrum reports were in complete agreement with the chemical structure. 
The synthesized compounds were screened for in-vitro anti-microbial 
activity by disc diffusion method as well as well diffusion method and in-vitro 
anti-cancer activity by MTT assay method. Among the evaluated compound, 
three compounds such as IM3 [(3Z)-3-(benzylimino)-1-[(diphenylamino) 
methyl]-1, 3-dihydro-2H-indol-2-one], IM4 [(3Z)-3-(benzylimino)-1-[(piperazin-
1-yl methyl)-1, 3-dihydro-2H-indol-2-one]  & IM20 [2-{[(3Z)-3-(benzylimino)2-
oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole-1,3(2H)-dione]  have good 
in-vitro anti-microbial activity at a dose of 50 and 100 µg/0.1 mL, when 
compared to standard drug Ciprofloxacin at a dose of 10 µg/0.1 mL.Among 
the evaluated compounds, two compounds such as IM3 [(3Z)-3-(benzylimino)-
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1-[(diphenylamino) methyl]-1, 3-dihydro-2H-indol-2-one]  & IM20 2-{[(3Z)-3-
(benzylimino)2-oxo-2,3-dihydro-1H-indol-1yl)methyl]}-1H-isoindole-1,3(2H)-
dione have good in-vitro anti-cancer activity with IC50 0.392 µg/mL  and 0.327 
µg/mL  aagainst human cervical cancer cell line (HeLa cell line) when 
compared to standard about 5FU with IC50 0.21 µg/mL.  
   From the above facts it can be suggested that the benzylimino-isatin 
mannich base derivatives finds an interesting field of research because of 
their varied pharmacological activities. 
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LIST OF ABBREVIATIONS 
 C2H5OH                        Ethanol 
 CH3COOH             Acetic acid 
 HCHO                  Formaldehyde 
 CO2           Carbon dioxide 
 CHCl3                   Chloroform 
 Pet.ether       Petroleum ether 
 CDCl3                                     Deuterated chloroform 
 DMSO                          Dimethyl sulfoxide 
 Std       Standard 
 Mm        Millimetre 
 µg        Microgram 
 ML       Milliliter 
 CFU                              Colony forming units 
 WHO        World health organization 
 IR       Infra-red 
 NMR                Nuclear magnetic resonance 
 TLC                              Thin layer chromatography 
 MTT        3-(4,5-dimethylthiazole-2-yl)-2,5-  
    diphenyltetrazolium bromide 
 IS1        Benzylimino-isatin 
 IM1                        Benzylimino-isatin mannich base 1 
 IM3        Benzylimino-isatin mannich base 3 
 IM4        Benzylimino-isatin mannich base 4 
 IM5        Benzylimino-isatin mannich base 5 
 IM19                              Benzylimino-isatin mannich base 19 
 IM20                               Benzylimino-isatin mannich base 20 
 E.coli                   Escherichia coli. 
 P.aeruginosa         Pseudomonas aeruginosa 
 S.aureus                Staphylococcus aureus 
 B.substilus              Bacillus subtilis                   
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Peak Intensity Corr. Intensity Base (H) Base (L) Area Corr. Area Comment
1 457.13 67.95 3.71 468.70 420.48 1317.481 48.711
2 489.92 59.31 9.07 509.21 468.70 1438.315 160.193
3 621.08 56.34 2.87 634.58 574.79 2430.518 78.907
4 696.30 32.65 21.26 723.31 659.66 3423.393 508.428
5 752.24 25.35 34.84 812.03 723.31 4205.491 1049.000
6 827.46 73.23 2.64 839.03 812.03 681.284 32.152
7 966.34 70.67 3.08 985.62 950.91 961.131 49.661
8 1024.20 59.68 12.33 1045.42 985.62 1978.923 328.229
9 1111.00 58.23 5.39 1126.43 1083.99 1630.183 106.549
10 1193.94 39.38 15.71 1230.58 1165.00 3459.371 495.452
11 1292.31 49.33 3.51 1311.59 1263.37 2344.873 79.817
12 1332.81 44.02 9.31 1359.82 1311.59 2449.809 207.544
13 1396.46 46.70 6.97 1421.54 1359.82 3059.894 212.449
14 1452.40 38.25 3.84 1458.18 1421.54 2001.083 38.931
15 1469.76 28.13 15.84 1504.48 1458.18 2687.841 273.313
16 1516.05 53.17 2.29 1533.41 1504.48 1322.180 32.534
17 1618.28 24.94 22.00 1635.64 1558.48 4545.770 714.691
18 1716.65 14.50 50.80 1849.73 1635.64 9288.119 3311.258
19 1955.82 93.57 2.00 2002.11 1924.96 417.698 74.417
20 2819.93 58.12 3.66 2852.72 2752.42 3935.799 173.801
21 2881.65 57.42 3.25 2920.23 2852.72 2766.803 113.967
22 3059.10 43.55 3.14 3078.39 3041.74 2008.357 54.027
23 3199.91 42.40 11.87 3574.10 3107.32 19725.670 2913.809
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Peak Intensity Corr. Intensity Base (H) Base (L) Area Corr. Area Comment
1 491.85 61.16 6.89 513.07 414.70 3118.099 213.026
2 700.16 38.53 16.61 725.23 680.87 2306.288 310.113
3 754.17 23.83 37.01 800.46 725.23 3925.378 1135.474
4 945.12 58.74 5.02 964.41 893.04 2559.620 167.563
5 1053.13 33.17 3.63 1087.85 1031.92 3620.944 104.817
6 1101.35 36.14 4.32 1141.86 1087.85 3218.435 106.233
7 1155.36 42.43 4.03 1168.86 1141.86 1499.134 53.236
8 1186.22 41.70 4.22 1209.37 1168.86 2285.718 90.187
9 1247.94 39.12 3.71 1265.30 1209.37 3267.032 100.512
10 1348.24 25.07 15.55 1417.68 1323.17 5947.207 632.934
11 1467.83 20.55 15.28 1479.40 1417.68 3909.017 295.920
12 1487.12 26.93 10.85 1514.12 1479.40 2019.024 90.420
13 1610.56 15.06 31.89 1643.35 1556.55 5504.541 1000.025
14 1716.65 10.00 52.99 1851.66 1643.35 8690.824 2705.006
15 1953.89 95.55 1.72 2013.68 1924.96 296.786 65.295
16 2870.08 46.86 5.79 2918.30 2835.36 4161.179 213.577
17 2941.44 48.41 5.59 2999.31 2918.30 3692.518 154.093
18 3059.10 52.64 4.34 3103.46 3039.81 2827.461 111.987
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Peak Intensity Corr. Intensity Base (H) Base (L) Area Corr. Area Comment
1 486.06 61.48 8.83 514.99 464.84 1698.913 203.166
2 526.57 67.71 1.78 542.00 514.99 846.059 23.223
3 623.01 58.48 4.10 636.51 582.50 2029.765 62.516
4 651.94 53.27 5.25 665.44 636.51 1268.644 74.169
5 698.23 30.47 23.02 725.23 665.44 3334.751 566.208
6 752.24 20.10 40.36 792.74 725.23 3792.330 1273.229
7 829.39 58.16 14.68 846.75 792.74 1733.540 280.937
8 1006.84 21.73 45.73 1039.63 929.69 4995.347 1553.262
9 1051.20 58.66 3.83 1058.92 1039.63 755.436 42.085
10 1072.42 51.09 9.38 1083.99 1058.92 1106.566 115.196
11 1165.00 15.98 40.75 1226.73 1083.99 8938.594 2826.762
12 1286.52 20.19 14.36 1301.95 1226.73 4795.139 409.788
13 1311.59 27.27 4.42 1327.03 1301.95 1750.685 53.558
14 1348.24 20.52 15.37 1394.53 1327.03 4760.180 466.300
15 1409.96 34.05 4.25 1421.54 1394.53 1722.635 54.499
16 1465.90 18.26 7.91 1477.47 1456.26 1643.578 86.981
17 1487.12 25.78 11.25 1504.48 1477.47 1778.863 135.781
18 1519.91 42.72 3.34 1535.34 1504.48 1721.008 56.214
19 1610.56 13.66 22.78 1637.56 1535.34 7040.021 841.497
20 1718.58 10.00 41.51 1803.44 1676.14 6319.133 1655.835
21 2804.50 16.91 21.92 2864.29 2515.18 20825.116 2195.408
22 2879.72 31.83 2.52 2895.15 2864.29 2062.896 36.850
23 2937.59 26.77 8.76 2989.66 2895.15 6419.585 343.198
24 3057.17 30.14 3.21 3076.46 3039.81 2499.253 57.250
500750100012501500175020002500300035004000
cm-1
0
25
50
75
100
%T
3
4
8
9
.2
3
2
9
5
4
.9
5
2
8
9
5
.1
5
2
3
6
8
.5
9
1
7
7
2
.5
8
1
7
0
7
.0
0
1
6
1
0
.5
6
1
4
8
9
.0
5
1
4
6
5
.9
0
1
4
2
3
.4
7
1
3
9
4
.5
3
1
3
5
5
.9
6
1
3
2
8
.9
5
1
2
3
6
.3
7
1
1
7
4
.6
5
1
1
2
2
.5
7
1
0
9
1
.7
1
1
0
6
0
.8
5
9
7
7
.9
1
9
3
3
.5
5
8
4
8
.6
8
8
0
4
.3
2
7
5
6
.1
0
7
2
9
.0
9
7
0
9
.8
0
6
2
6
.8
7
5
6
5
.1
4
5
3
2
.3
5
4
1
6
.6
2
IM20
Peak Intensity Corr. Intensity Base (H) Base (L) Area Corr. Area Comment
1 416.62 71.49 1.88 426.27 399.26 741.776 23.017
2 532.35 48.02 22.67 553.57 474.49 2925.407 570.887
3 565.14 55.16 17.75 582.50 553.57 1009.125 237.531
4 626.87 56.75 19.38 646.15 582.50 1980.419 448.525
5 709.80 56.27 8.76 719.45 677.01 1498.238 138.733
6 729.09 36.89 30.72 744.52 719.45 1140.075 365.627
7 756.10 68.04 8.94 785.03 744.52 1030.819 139.759
8 804.32 72.31 7.89 815.89 785.03 712.346 102.513
9 848.68 67.71 6.64 860.25 815.89 1174.252 118.898
10 933.55 39.29 13.24 945.12 860.25 3661.073 339.562
11 977.91 27.57 26.54 1012.63 945.12 3735.909 647.606
12 1060.85 36.50 21.99 1078.21 1012.63 3228.876 519.239
13 1091.71 48.86 8.59 1103.28 1078.21 1173.184 107.752
14 1122.57 50.27 7.45 1139.93 1103.28 1696.609 145.373
15 1174.65 68.75 5.41 1184.29 1165.00 555.261 56.794
16 1236.37 66.49 9.99 1251.80 1211.30 1114.137 148.161
17 1328.95 38.39 18.86 1342.46 1251.80 3415.938 297.882
18 1355.96 38.79 18.71 1381.03 1342.46 1944.709 368.128
19 1394.53 48.53 17.14 1411.89 1381.03 1284.921 230.385
20 1423.47 56.54 14.98 1440.83 1411.89 994.673 202.568
21 1465.90 58.87 17.90 1479.40 1440.83 1263.233 379.295
22 1489.05 72.07 6.66 1508.33 1479.40 654.648 78.385
23 1610.56 55.24 19.41 1625.99 1554.63 2028.235 474.584
24 1707.00 10.00 62.74 1759.08 1625.99 7170.879 3523.437
25 1772.58 47.56 29.31 1853.59 1759.08 1681.176 346.835
26 2368.59 91.21 2.62 2393.66 2351.23 304.273 51.590
27 2895.15 81.67 5.57 2929.87 2852.72 1228.731 249.568
28 2954.95 76.59 8.15 2968.45 2929.87 699.994 127.973
29 3489.23 42.39 51.01 3624.25 3113.11 11252.437 6656.300
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IM3
No. Peak Intensity Corr. Intensity Base (H) Base (L) Area Corr. Area Comment
1 746.45 56.56 5.57 914.26 732.95 4526.686 -192.067
2 1018.41 10.00 77.89 1085.92 933.55 4926.741 3092.515
3 1114.86 83.11 5.56 1165.00 1085.92 1026.650 170.478
4 1313.52 85.33 3.40 1328.95 1271.09 675.229 64.006
5 1415.75 79.43 3.64 1435.04 1350.17 1452.560 153.513
6 1452.40 77.98 4.12 1481.33 1435.04 916.904 94.215
7 1492.90 78.04 6.17 1533.41 1481.33 851.142 124.281
8 1593.20 83.33 6.45 1612.49 1570.06 541.203 113.169
9 1651.07 85.99 2.18 1664.57 1624.06 515.215 39.247
10 1984.75 95.92 3.04 2000.18 1971.25 77.741 48.774
11 2031.04 95.02 2.53 2048.40 2023.33 88.776 34.172
12 2831.50 76.81 11.74 2870.08 2709.99 1707.950 342.582
13 2945.30 73.09 12.88 3026.31 2870.08 3039.946 848.618
750100012501500175020002500300035004000
cm-1
0
25
50
75
100
%T
2
9
4
5
.3
0
2
8
3
1
.5
0
2
3
6
4
.7
3
2
0
3
1
.0
4
1
9
8
0
.8
9
1
4
5
2
.4
0
1
4
1
1
.8
9
1
2
9
0
.3
8
1
1
1
4
.8
6
1
0
2
0
.3
4
IM5
No. Peak Intensity Corr. Intensity Base (H) Base (L) Area Corr. Area Comment
1 1020.34 10.00 76.93 1074.35 950.91 4590.217 2982.616
2 1114.86 82.38 5.09 1159.22 1074.35 1224.119 164.037
3 1290.38 87.50 2.13 1305.81 1263.37 468.975 40.777
4 1411.89 79.13 3.00 1433.11 1327.03 1768.118 129.340
5 1452.40 76.10 6.29 1527.62 1433.11 1599.143 194.168
6 1980.89 97.47 1.52 1988.61 1965.46 36.264 18.769
7 2031.04 95.47 1.78 2048.40 2023.33 91.548 22.099
8 2364.73 94.62 1.96 2397.52 2349.30 174.677 32.471
9 2831.50 74.00 13.01 2873.94 2709.99 2107.126 462.225
10 2945.30 70.75 12.87 3022.45 2873.94 3245.503 811.560
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IM19
No. Peak Intensity Corr. Intensity Base (H) Base (L) Area Corr. Area Comment
1 1020.34 10.00 77.65 1082.07 941.26 4733.399 3000.508
2 1112.93 79.33 9.38 1182.36 1082.07 1320.304 272.259
3 1452.40 77.20 5.50 1498.69 1435.04 1180.854 171.299
4 1539.20 88.30 1.37 1550.77 1529.55 233.669 14.904
5 1651.07 83.56 2.65 1664.57 1624.06 605.820 53.305
6 1938.46 98.11 1.30 1953.89 1930.74 24.678 13.149
7 1984.75 97.38 2.20 2002.11 1967.39 50.302 35.815
8 2187.28 97.82 1.21 2202.71 2169.92 52.040 20.278
9 2357.01 95.42 1.43 2399.45 2345.44 171.305 31.016
10 2831.50 75.82 11.93 2862.36 2709.99 1663.351 319.595
11 2943.37 73.00 12.49 3024.38 2862.36 3175.602 825.682
12 3647.39 92.87 2.00 3660.89 3637.75 140.465 24.951
13 3672.47 94.08 2.27 3699.47 3660.89 164.105 36.209
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IM1
Current Data Parameters
NAME          03_Kaniga
EXPNO                 3
PROCNO                1
F2 - Acquisition Parameters
Date_          20170703
Time              10.04
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                   32
DS                    0
SWH            6410.256 Hz
FIDRES         0.195625 Hz
AQ            2.5559039 sec
RG                  144
DW               78.000 usec
DE                 6.50 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.50 usec
PL1               -3.00 dB
PL1W        13.42244530 W
SFO1        400.2330017 MHz
F2 - Processing parameters
SI               131072
SF          400.2300191 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 ppm
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IM4
Current Data Parameters
NAME          03_Kaniga
EXPNO 2
PROCNO 1
F2 - Acquisition Parameters
Date_ 20170703
Time 9.58
INSTRUM spect
PROBHD   5 mm PABBO BB-
PULPROG zg
TD 32768
SOLVENT CDCl3
NS 32
DS 0
SWH 6410.256 Hz
FIDRES 0.195625 Hz
AQ 2.5559039 sec
RG 144
DW 78.000 usec
DE 6.50 usec
TE 298.0 K
D1 2.00000000 sec
TD0 1
======== CHANNEL f1 ========
NUC1 1H
P1 13.50 usec
PL1 -3.00 dB
PL1W 13.42244530 W
SFO1 400.2330017 MHz
F2 - Processing parameters
SI 131072
SF 400.2300185 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 ppm
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IS1
Current Data Parameters
NAME          03_Kaniga
EXPNO                 4
PROCNO                1
F2 - Acquisition Parameters
Date_          20170703
Time              10.13
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG              zg
TD                32768
SOLVENT           CDCl3
NS                   32
DS                    0
SWH            6410.256 Hz
FIDRES         0.195625 Hz
AQ            2.5559039 sec
RG                  114
DW               78.000 usec
DE                 6.50 usec
TE                298.0 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.50 usec
PL1               -3.00 dB
PL1W        13.42244530 W
SFO1        400.2330017 MHz
F2 - Processing parameters
SI               131072
SF          400.2300208 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
PC                 1.00
 
 
 
 
 
 
 
 
